Caris Life Sciences

CAI

Market cap $8.99B

IRVING, Texas , Oct. 14, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, will unveil six studies at the European Society for Medical Oncology (ESMO) Congress 2025, in Berlin, Germany from October 17-21, 2025. These presentations highlight the transformative power of multiomics, a scientific approach that integrates data from multiple biological layers to achieve a comprehensive understanding of biological systems and disease.

Caris Life Sciences stands out for its broad molecular and AI-driven cancer diagnostics but faces upcoming volatility as the IPO lock-up expires on 15 December 2025. CAI's revenue growth is robust, driven primarily by molecular profiling, but overdependence on this segment and execution across diverse fronts pose risks. The company boasts industry-leading breadth—tissue and blood testing, early detection, monitoring, and biopharma partnerships—but faces strong, focused competitors in each segment.

IRVING, Texas , Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek®. This FDA-approved assay is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies.

IRVING, Texas , Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients. The study found that the cancer drug T-DXd worked better for patients whose tumors are hormone receptor (HR)-positive, helping them stay on treatment longer than those taking SG, across all HER2-negative groups.

IRVING, Texas , Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported total revenue of $181.4 million, an increase of 81.3% over the corresponding prior year period.

Groundbreaking study in Nature Communications highlights AI's role in transforming immunotherapy decisions and precision oncology IRVING, Texas , Aug. 6, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a new study in Communications Medicine, a Nature portfolio journal, demonstrating that Caris' AI-based image analysis model has the potential to more accurately predict cancer biomarkers and patient survival than the conventional companion diagnostic (CDx) methods. By analyzing hematoxylin and eosin (H&E) images, the study demonstrated that Caris' AI model can improve the assessment of critical cancer biomarkers and impact patient survival outcomes in breast and colorectal cancers.

Caris GPSai™ utilizes deep learning to significantly improve diagnostic accuracy for cancers of unknown primary and misclassified tumors IRVING, Texas , Aug. 5, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, recently published a study on the development and validation of Caris' latest version of Caris GPSai™ in AACR's Cancer Research Communications Journal. Caris GPSai is a clinically validated deep learning multi-layer AI that leverages comprehensive whole exome and whole transcriptome sequencing (WES/WTS) to significantly improve diagnostic accuracy for cancers of unknown primary (CUP) and identify patients who have potentially misdiagnosed tumors.

IRVING, Texas , July 23, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m.

Validation was shared via a Letter to the Editor in the New England Journal of Medicine IRVING, Texas , July 22, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published original data in the New England Journal of Medicine independently validating recent findings on tumor-infiltrating clonal hematopoiesis (TI-CH), and further reinforcing its leadership in precision oncology.    As a champion of scientific collaboration, Caris appreciated the opportunity to validate a recent study published in the New England Journal of Medicine, which brought attention to the clinical challenge of TI-CH—blood-derived mutations that infiltrate tumor tissue and are often misinterpreted as tumor-specific mutations.

Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas , July 8, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature journal, demonstrating the accuracy and clinical utility of the Caris Assure® blood-based biopsy assay across the cancer continuum.